Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EDEN Bioscience was an agricultural biotechnology company that pioneered the use of harpin proteins to stimulate natural plant defense and growth mechanisms. Based on technology licensed from Cornell University, the company developed products like Messenger that triggered systemic acquired resistance (SAR) in crops, providing protection against a broad spectrum of diseases and pests while enhancing yield. Although the company successfully achieved EPA registration and commercialized several products, it struggled with market adoption and financial sustainability. In 2007, EDEN Bioscience sold its harpin technology and intellectual property to Plant Health Care and subsequently completed a formal liquidation process.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on EDEN Bioscience.